Publications and Talks – Nanomedicines

Research Articles

Reviews

Editorials

Full Research Articles

Osipova N, Budko A, Maksimenko O, Shipulo E, Vanchugova L, Chen W, Gelperina S, Wacker MG (2023); Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations, Pharmaceutics (10.3390/pharmaceutics15041258, IF=6.525 [2023])
Wallenwein CM, Ashtikar M, Hofhaus G, Haferland I, Thurn M, König A, Pinter A, Dressman J, Wacker MG (2022); How Wound Environments Trigger the Release from Rifampicin-loaded Liposomes, Int. J. Pharm. (10.1016/j.ijpharm.2023.122606, IF=6.51 [2021])
Lim XC, Huang C, Yatim SMJM, Chong SY, Tan SH, Yang X, Heldt CL, Pedersen J, Talanker M, Modh H, Wacker MG, Pastorin G, Chan SP, Richards AM, Charles CJ, Chan MY, Wang JW (2022); Temporal changes in extracellular vesicle hemostatic protein composition predict favourable left ventricular remodeling after acute myocardial infarction, Int. J. Mol. Sci. (10.3390/ijms24010327, IF=6.208 [2021])
Wallenwein CM, Weigel V, Hofhaus G, Dhakal N, Schatton W, Gelperina S, Groeber-Becker FK, Dressman J, Wacker MG (2022); Pharmaceutical Development of Nanostructured Vesicular Hydrogel Formulations of Rifampicin for Wound Healing, Int. J. Mol. Sci. (10.3390/ijms232416207, IF=6.208 [2021])
Li Z, Ramirez G, Tang R, Cheong KXP, Nair M, Henderson S, Morimoto B, Liu J, Kaasgaard T, Boyd B, Wacker MG (2022); Modeling digestion, absorption, and ketogenesis after administration of tricaprilin formulations to humans; Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2022.11.022, IF=5.589 [2021])
Mast MP, Mesquita L, Gan K, Gelperina S, das Neves J, Wacker MG (2022); Encapsulation and release of hydrocortisone from proliposomes govern vaginal delivery, Drug Del. Trans. Res. (10.1007/s13346-022-01263-x, IF=5.671 [2021])
Lee CK, Zhang S, Venkatesan G, Lim I, Chong SY, Wang JW, Goh WJ, Panczyk T, Tay YZ, Hu J, Ng WK, Wacker MG and Toh WS and Pastorin G (2021); Enhanced skin penetration of berberine from proniosome gel attenuates pain and inflammation in a mouse model of osteoarthritis, Biomat. Sci. (10.1039/D1BM01733K, IF=6.843 [2020])
Haferland I, Wallenwein CM, Ickelsheimer T, Diehl S, Wacker MG, Schiffmann S, Buerger C, Kaufmann R, Koenig A and Pinter A (2021); Mechanism of anti-inflammatory effects of Rifampicin in an ex vivo culture system of Hidradenitis Suppurativa, Exp. Dermatol. (10.1111/exd.14531, IF=3.960 [2020]).
Hajba-Horváth E, Fodor-Kardos A, Shah N, Wacker MG and Feczko T (2021); Sustainable stabilizer-free nanoparticle formulations of valsartan using Eudragit® RLPO, Int. J. Mol. Sci. (10.3390/ijms222313069, IF=5.923 [2020])
Mast MP, Modh H, Knoll J, Fecioru E, Wacker MG (2021); An Update to Dialysis-based Drug Release Testing – Data Analysis and Validation using the Pharma Test Dispersion Releaser. Pharmaceutics (10.3390/pharmaceutics13122007, IF=6.321 [2020])
Modh H, Fang DJ, Ou YH, Yau JNN, Kovshova T, Nagpal S, Knoll J, Wallenwein CM, Maiti K, Bhowmick S, Gelperina S, Pastorin G, Wacker MG (2021); Injectable Drug Delivery Systems of Doxorubicin Revisited: In Vitro-In Vivo Relationships Using Human Clinical Data, Int. J. Pharm. (10.1016/j.ijpharm.2021.121073, IF=5.875 [2020])
Neupane YR and Huang C, Wang X, Chng WH, Venkatesan G, Zharkova O, Wacker MG, Czarny B, Storm G, Wang JW and Pastorin G (2021); Lyophilization Preserves the Intrinsic Cardioprotective Activity of Bioinspired Cell-Derived Nanovesicles, Pharmaceutics (10.3390/pharmaceutics13071052, IF=6.321 [2020])
Hering I, Eilebrecht E, Parnham MJ, Weiler M, Günday-Türeli N, Türeli AE, Modh H, Heng PWS, Böhmer W, Schäfers C, Fenske M, Wacker MG (2021); Microparticle formulations alter the toxicity of fenofibrate to the zebrafish Danio rerio embryo, Aquat. toxicol. (10.1016/j.aquatox.2021.105798, IF=4.344 [2020])
Kovshova T, Osipova N, Alekseeva A, Malinovskaya J, Belov A, Budko A, Pavlova G, Maksimenko O, Nagpal S, Braner S, Modh H, Balabanyan V, Wacker MG and Gelperina S (2021); Exploring the interplay between drug release and targeting of the doxorubicin-loaded polymer nanoparticles for brain delivery, Molecules (10.3390/molecules26040831, IF=4.411 [2020])
Jung F and Thurn M, Krollik K, Li D, Dressman J, Alig E, Fink L, Schmidt MU, Wacker MG (2021); Sustained-release hot melt extrudates of the weak acid TMP-001: A case study using PBB modelling, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2021.01.007, IF=5.571 [2020])
Gao GF, Ashtikar M, Kojima R, Yoshida T, Kaihara M, Tajiri T, Shanehsazzadeh S, Modh H, Wacker MG (2021); Predicting drug release and degradation kinetics of long-acting microsphere formulations of tacrolimus for subcutaneous injection, J. Control. Release (10.1016/j.jconrel.2020.11.055, IF=9.776 [2020])
Jung F, Thurn M, Krollik K, Gao GF, Hering I, Eilbrecht E, Emara Y, Weiler M, Günday-Türeli N, Türeli E, Parnham MJ, Wacker MG (2020); Predicting the environmental emissions arising from conventional and nanotechnology-related pharmaceutical drug products, Environ. Res. (10.1016/j.envres.2020.110219, IF=5.715 [2019])
Ou YH, Zou S, Goh WJ, Chong SY, Venkatesan G, Wacker MG, Storm G, Wang JW, Czarny B, Pastorin G and Woon ECY (2020); Micro Cell Vesicle Technology (mCVT): A Novel Hybrid System of Gene Delivery for Hard-To-Transfect (HTT) Cells, Nanoscale (10.1039/D0NR03784B, IF=6.895 [2019])
Gao GF, Thurn M, Wendt B, Parnham MJ, Wacker MG (2020); A sensitive in vitro performance assay reveals the in vivo drug release mechanisms of long-acting medroxyprogesterone acetate microparticles, Int. J. Pharm. (10.1016/j.ijpharm.2020.119540, IF=4.845 [2019])
Nagpal S and Braner S, Modh H, Tan AXX, Mast MP, Chichakly K, Albrecht V, Wacker MG (2020); A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2020.06.004, IF=4.604 [2019])
Hering I, Eilebrecht E, Parnham MJ, Günday-Türeli N, Türeli AE, Weiler M, Schäfers C, Fenske M, Wacker MG (2020); Evaluation of potential environmental toxicity of polymeric nanomaterials and surfactants, Environ. Toxicol. Pharmacol. (10.1016/j.etap.2020.103353, IF=3.292 [2019])
Jablonka L, Ashtikar M, Gao GF, Thurn M, Modh H, Wang JW, Preuß A, Scheglmann D, Albrecht V, Röder B, Wacker MG (2020); Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2020.02.001, IF=4.604 [2019])
Feczkó T, Piiper A, Pleli T, Schmithals C, Denk D, Hehlgans S, Rödel F, Vogl TJ, Wacker MG (2019); Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques, Pharmaceutics (10.3390/pharmaceutics11100489, IF=4.773 [2018])
Wallenwein CM and Villa Nova M, Janas C, Jablonka L, Gao GF, Thurn M, Albrecht V, Wiehe A, Wacker MG (2019); A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2019.08.010, IF=4.604 [2019])
Jablonka L, Ashtikar M, Gao G, Jung F, Thurn M, Preuß A, Scheglmann D, Albrecht V, Röder B, Wacker MG (2019); Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans, J. Control. Release (10.1016/j.jconrel.2019.06.029, IF=7.908 [2018])
Villa Nova M, Nothnagel L, Thurn M, Travassos PB, Herculano LS, Bittencourt PRS, Novello CR, Bazotte RB, Wacker MG, Bruschi ML (2018); Development study of pectin/Surelease microparticles for the delivery of L-alanyl-L-glutamine dipeptide, Food Hydrocoll. (10.1016/j.foodhyd.2018.11.038, IF=5.089 [2017])
Feczkó T, Piiper A, Ansar S, Blixt FW, Ashtikar M, Schiffmann S, Ulshöfer T, Parnham MJ, Harel Y, Israel LL, Lellouche JP, Wacker MG (2018); Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy, J. Control. Release (10.1016/j.jconrel.2018.11.017, IF= 7.908 [2018])
Nothnagel L and Jung F, Rossmanith T, Thurn M, Ashtikar M, Geisslinger G, Parnham MJ, Wacker MG (2018); Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2018.11.012, IF= 4.773 [2018])
Jung F and Nothnagel L, Gao F, Thurn M, Vogel V, Wacker MG (2018); A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2018.03.010, IF= 4.773 [2018])
Janas C, Kirsamer L, Mast MP, Agioni C, Gao F, Mäntele W, Dressman J, Wacker MG (2017); The dispersion releaser technology is an effective method to test the drug release from nanosized carriers, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2017.02.006, IF= 4.491 [2017])
Beyer S and Xie L, Schmidt M, de Bruin N, Ashtikar M, Rüschenbaum S, Lange CM, Vogel V, Mäntele W, Parnham MJ, Wacker MG (2016); Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques, J. Control. Release, (10.1016/j.jconrel.2016.06.013, IF=7.786 [2016])
Janas C, Mostaphaoui Z, Schmiederer L, Bauer J, Wacker MG (2016); Novel polymeric micelles for drug delivery: Material characterization and formulation screening, Int. J. Pharm. (10.1016/j.ijpharm.2016.05.029, IF=3.649 [2016])
Beyer S, Moosmann A, Kahnt AS, Ulshöfer T, Parnham MJ, Ferreirós N, Wacker MG (2015); Drug release and targeting: The versatility of polymethacrylate nanoparticles for peroral administration revealed by using an optimized in vitro-toolbox, Pharm. Res. (10.1007/s11095-015-1759-2, IF=3.896 [2015])
Villa Nova M, Janas C, Schmidt M, Ulshöfer T, Gräfe S, Schiffmann S, de Bruin N, Wiehe A, Albrecht V, Parnham MJ, Bruschi ML, Wacker MG (2015); Nanocarriers for photodynamic therapy – Rational formulation design and medium-scale manufacture, Int. J. Pharm. (10.1016/j.ijpharm.2015.06.024, IF=3.994 [2015])
Xie L, Beyer S, Vogel V, Wacker MG, Mäntele W (2015); Assessing the Drug Release from Nanoparticles: Overcoming the Shortcomings of Dialysis by Using Novel Optical Techniques and a Mathematical Model, Int. J. Pharm. (10.1016/j.ijpharm.2015.03.080, IF=3.994 [2015])
Beyer S, Xie L, Graefe S, Vogel V, Dietrich K, Wiehe A, Albrecht V, Maentele W, Wacker MG (2015); Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery, Pharm. Res. (10.1007/s11095-014-1569-y, IF=3.896 [2015])
Wacker MG, Altinok M, Urfels S, Bauer J (2014); Nanoencapsulation of superparamagnetic particles of iron oxide into human serum albumin nanoparticles, Beilstein J. Nanotechnol. (10.3762/bjnano.5.235, IF=2.7 [2014])
Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C,Gehrmann M, Rödel C, Kreuter J, Rödel F (2013); Targeting by cmHsp70.1-antibody coated and Survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells, J. Control. Release (10.1016/j.jconrel.2013.08.020, IF=6.881 [2013])
Hofmann B, Rödl CB, Fischer AS, Maier TJ, Michel AA, Hoffmann M, Rau O, Awwad K, Pellowska M, Wurglics M, Wacker M, Živković A, Fleming I, Schubert-Zsilavecz M, Stark H, Schneider G, Steinhilber D (2011); Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor, Br. J. Pharmacol. (10.1111/j.1476-5381.2011.01707.x, IF=4.89 [2011])
Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stockburger T, Marstaller T, Vogel V (2011); A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation, Int. J. Pharm. (10.1016/j.ijpharm.2011.04.046, IF=3.350[2011])
Löw K, Wacker M, Wagner S, Langer K, von Briesen H (2010); Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells, Nanomedicine (10.1016/j.nano.2010.12.003, IF=5.044[2011])
Preuss A, Hackbarth S, Wacker M, Knobloch T, Langer K, Röder B (2010); Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems, J. Control. Release (10.1016/j.jconrel.2010.07.089, IF=7.641[2010])
Zheng SZ, Löw K, Wacker M, Wiehe A, Wagner S, Langer K, von Briesen H, Zou SQ (2010); Interaction and cytotoxicity of mTHPC and mTHPC complexes in Jurkat cells. Chin. J. Exp. Surg. 10: 1463-1465. (ISSN 1001-9030 Article in Chinese)
Chen K, Wacker M, Hackbarth S, Ludwig C, Langer K, Roeder B (2010); Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems, J. Photochem. Photobiol. B (10.1016/j.jphotobiol.2010.08.006, 2.184[2009])
Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K (2010); Photosensitizer loaded HSA nanoparticles I: Preparation and photophysical properties, Int. J. Pharm. (10.1016/j.ijpharm.2010.11, IF=3.607)
Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Roeder B (2009); Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations, J. Photochem. Photobiol. B (0.1016/j.jphotobiol.2009.04.006, IF=2.184 [2009])

Review Articles

Pastorin G, Benetti C, Wacker MG (2023); From In Vitro to In Vivo: A Comprehensive Guide to IVIVC Development for Long-Acting Therapeutics, Adv. Drug. Del. Rev. (Accepted for publication)
Barton A, Digigow R, Flühmann B, Wacker MG (2023); Putting square pegs in round holes: why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes, Eur. J. Pharm. Biopharm. (10.1016/j.ejpb.2023.04.025, IF=5.589 [2021])
Lian MQ, Chng WH, Liang J, Yeo HQ, Lee CK, Belaid M, Tollemeto M, Wacker MG, Bertrand Czarny B, Pastorin G (2022); Plant-derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applications, J. Extracell. Ves. (10.1002/jev2.12283, IF=21.224 [2021])
Miri AH, Kamankesh M, Llopis-Lorente A, Liu C, Wacker MG, Haririan I, Aghdaei HA, Hamblin MR, Abbas Yadegar A, Rad-Malekshahi M and Zali MR (2022); The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications, Front. Pharmacol. (10.3389/fphar.2022.917184, IF=5.988[2020])
D’Arcy DM, Wacker MG, Klein S, Shah V, Burke MD, Hunter G, Xu H (2022); In-Vitro Product Performance of Parenteral Drug Products: View of the USP Expert Panel, Dissolution Tech (10.14227/DT290422P204, IF=0.978 Reprint of USP stimuli article)
Villa Nova M, Gan K, Wacker MG (2022); Biopredictive Tools for the Development of Injectable Drug Products; Exp. Opinion Drug Del. (10.1080/17425247.2022.2081682, IF=6.48[2020])
Wacker MG, Lu X, Burke M, Nir I, Fahmy R (2022); Testing the In-Vitro Product Performance of Nanomaterial-Based Drug Products: View of the USP Expert Panel, Dissolution Tech (10.14227/DT290122P6, IF=0.978 Reprint of USP stimuli article)
Villa Nova M and Lin TP, Shanehsazzadeh S, Jain K, Ng SCY, Wacker R, Chichakly K, Wacker MG (2022); Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence. Front. Dig. Health (10.3389/fdgth.2022.799341, no IF)
Barton AE, Borchard G, Wacker MG, Pastorin G, Saleem IY, Chaudary S, Elbayoumi T, Zhao Z, Flühmann B (2021); Commentary: Need for Expansion of Pharmacy Education Globally for the Growing Field of Nanomedicine. Pharmacy (10.3390/pharmacy10010017, no IF)
Li D, Chow PY, Lin TP, Cheow C, Li Z, Wacker MG (2021); Simulate SubQ – The Methods and the Media, J. Pharm. Sci. (10.1016/j.xphs.2021.10.031, IF=3.534 [2020])
Mast MP , Modh H, Champanhac C, Wang JWW, Storm G, Krämer J, Mailänder V, Pastorin G, Wacker MG (2021); Nanomedicine at the crossroads – A quick guide for IVIVC, Adv. Drug Del. Rev. (10.1016/j.addr.2021.113829, IF=15.47 [2020])
Ou YH, Liang J, Czarny B, Wacker MG, Yu V, Wang JW, Pastorin G (2021); Extracellular Vesicle (EV) biohybrid systems for cancer therapy: recent advances and future perspectives, Sem. Cancer Biol. (10.1016/j.semcancer.2021.02.006, IF=11.090)
Fecioru E, Klein M, Krämer J, Wacker MG (2019); In vitro performance testing of nanoparticulate drug products for parenteral administration, Diss. Tech. (10.14227/DT260319P28, IF=0.915)
Marques MRC, Choo Q, Ashtikar M, Rocha TC, Bremer-Hoffmann S, Wacker MG (2019); Nanomedicines – Tiny particles and big challenges, Adv. Drug Del. Rev. (10.1016/j.addr.2019.06.003, IF=13.30 [2019])
Nothnagel L, Wacker MG (2018); Mikro- und Nanoarzneiformen in Entwicklung und Qualitätskontrolle – Welche Methoden eignen sich für den Test auf Wirkstofffreisetzung – Teil 2, Pharm. Ind. 11/2018 (Article in German, no IF)
Nothnagel L, Wacker MG (2018); Mikro- und Nanoarzneiformen in Entwicklung und Qualitätskontrolle – Welche Methoden eignen sich für den Test auf Wirkstofffreisetzung – Teil 1, Pharm. Ind. 10/2018 (Article in German, No IF)
Nothnagel L, Wacker MG (2018); How to measure release from nanosized carriers, Eur. J. Pharm. Sci. (10.1016/j.ejps.2018.05.004, IF=3.532 [2018])
Ashtikar M, Wacker MG (2018); Nanotherapeutics for wound healing – Lost in translation?, Adv. Drug Del. Rev. 129, 194-218 (10.1016/j.addr.2018.03.005, IF=16.663 [2018])
Wacker MG, Proykova A, Santos GM (2016); Dealing with nanosafety around the globe – Regulation vs. Innovation, Int. J. Pharm. 509(1-2): 95-106 (10.1016/j.ijpharm.2016.05.015, IF=4.080 [2016])
Bergs JW, Wacker MG, Hehlgans S, Piiper A, Multhoff G, Rödel C,Rödel F (2015); The role of recent nanotechnology in enhancing the efficacy of radiation therapy, Biochim. Biophys. Acta (10.1016/j.bbcan.2015.06.008, IF=5.053 [2015])
Wacker MG (2014); Nanotherapeutics – Product Development Along the ‘Nanomaterial’ Discussion, J. Pharm. Sci. (10.1002/jps.23879, IF=3.007 [2013])
Wacker M (2013); Nanocarriers for intravenous injection – The long hard road to the market, Int. J. Pharm. (10.1016/j.ijpharm.2013.08.079, IF=3.458 [2012])

Editorials and Expert Meetings

Hermans A, Dorozynski P, Muzzio FJ, Li H, Nielsen S, Chen S, Reppas C, Klein S, Patel S, Wacker M, Thakker K, Pruessmann K, Seidlitz A, Ghosh TK, Yang Y, Willett D, Hochhaus G, Tay J, Liew CV, Heng PWS, Sun CC, Kraemer J, Marques MRC (2020); Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products, Diss. Tech. (10.14227/DT270220P52)
Wacker MG (2019); Frontiers in pharmaceutical nanotechnology, Beilstein J. Nanotechnology. (doi.org/10.3762/bjnano.10.244)
Ashtikar M, Mäder K, Klein M, Wunderlich K, Lozach P-Y, Gao F, Mende S, Strasser C, Dennison T, Marenchino M, Wacker, MG (2019); LOEWE Workshop Particle Characterization in Medicine and Biology, Pharm. Front. (10.20900/pf20190002)
Wacker MG (2017); Challenges in the drug release testing of next-generation nanomedicines – What do we know?, Mat. Tod. Proc. 2, 214-217 (10.1016/j.matpr.2017.09.189)

Patents and Patent Applications

2023 Wacker MG, Fähler B; A DISPERSION RELEASER; International Patent Application (PCT/SG2022/050594)
2016 Wacker MG, Beyer S, Parnham MJ, Maentele W, Vogel V, Xie (Kirsamer) L, COMPOSITION COMPRISING A BIOCOMPATIBLE AND BIODEGRADABLE POLYMER, NANOCARRIES AND A DRUG AND METHODS OF MAKING AND USING THE SAME; European Patent (EP3370694), US Patent (US20180318433) Japanese Patent (JP2018532785) Canadian Patent (CA3004363)
2015 Wacker MG, Janas C; DIALYSIS CELL FOR AN IN-VITRO RELEASE TEST APPARATUS, USE OF THE DIALYSIS CELL AND IN-VITRO RELEASE TEST APPARATUS, German Patent (DE102013015522), European Patent (EP3047267), International Patent (WO/2015/039749)
2011 Langer K, Wacker M, Röder B, Preuss A, Albrecht V, Gräfe S, Wiehe A, von Briesen H, Löw K, Wagner S; NANOPARTICLE CARRIER SYSTEMS BASED ON HUMAN SERUM ALBUMIN FOR PHOTODYNAMIC THERAPY; US Patent (US20110142948), European Patent (EP2509620), Chinese Patent (CN102740875), Canadian Patent (CA2784001), Brazilian Patent (BR112012013952), Japanese Patent (JP2013513609) Indian Patent (IN5995/CHENP/2012)

Book chapters

Huang C, Neupane YR, Xiong Chang, Lima Rawan, Shekhaniab, Czarny B, Wacker MG, Pastorin G, Wang JW; Extracellular vesicles in cardiovascular disease in Advances in Clinical Chemistry edited by Gregory Makowski, Elsevier Publishing Group (10.1016/bs.acc.2020.08.006)
Wacker MG, Janas C, Ferreira FS, Vieira FP; Manufacturing and Safety Guidelines for Manufactured Nanomaterials in Pharmaceutics in Biomedical applications of functionalized nanomaterials (1^st edn) edited by Bruno Sarmento and José das Neves, Elsevier Publishing Group (10.1016/B978-0-323-50878-0.00021-5)
Wacker MG; Nanomedicines – A Scientific Toy or an Emerging Market? in Polymer nanoparticles for nanomedicines: A Guide for Design, Preparation and Development (1^st edn) edited by Vauthier C and Ponchel G, Springer International (10.1007/978-3-319-41421-8_18)
Wacker MG; Suspensionen – Parenteralia, Ophthalmika und perorale Suspensionen: Teilchengrößen-wachstum, Stabilität, Freisetzung in Partikel in der Pharmaproduktion: Messtechnik – Detektion und Charakterisierung – Regulatorische Anforderungen (1^st edn) edited by Stienecker F, Editio Canto Verlag.

Keynote lectures

Wacker MG (11-2021); Translational Nanomedicine: Crossing Borders in Drug Delivery, Nano Singapore 2021 conference and exhibition (Hosted in Singapore)
Wacker MG (09-2021); Biopredictive Tools for the Development of Injectable Drug Products, 11^th American Drug Delivery and Formulation Summit (Hosted in USA)
Wacker MG (04-2021); Nanomedicines Revisited: A Facelift For Personalized Therapy?, 2^nd ExplainMyResearch Conference (Hosted in Singapore)
Wacker MG (09-2020); Nanomedicine Unleashed – Case Studies on Performance Testing, AAPS-NUS Student Chapter NUS-Monash Virtual Event (Hosted in Singapore)

Invited talks

Wacker MG (06-2023); Biopredictive Tools for Injectables: Long-Acting and Long-Circulating Systems, DISSO 2023, Mumbai (India)
Wacker MG (05-2023); Novel Complex Dosage Forms in Drug Delivery: Do We Need A New Biopredictive Toolbox?, PSTS 2023, Singapore (Singapore)
Wacker MG (02-2023); Nanotech meets Data Science: Biopredictive Methods in Drug Delivery, PharmNotts Industrial Talk 2023, Hosted in Semenyih (Malaysia)
Wacker MG (11-2022); Biopredictive Strategies for Injectables: Tomorrow’s In Vitro-In Silico Toolkit, 12^th Fresenius Global Preclinical Meeting, Hosted in Bad Homburg (Germany)
Wacker MG (10-2022); Injectable Nanomedicines: Biopredictive Release Testing and IVIVC, 12^thGlobal Summit on Regulatory Science, Singapore (Singapore)
Wacker MG (07-2022); Nanomedicine Ex Machina: Design Strategies Based on Clinical Relevance, Goethe Graduate Academy for Early Career Researchers Seminars, Frankfurt (Germany)
Wacker MG (07-2022); Nanomedicine Ex Machina: Design Strategies Based on Clinical Relevance, Fraunhofer IAP Seminars, Potsdam (Germany)
Wacker MG (06-2022); Biopredictive Tools for Injectable Dosage Forms, Global Drug Delivery & Formulation Summit, Berlin (Germany)
Wacker MG (05-2022); Nanomedicine Ex Machina: Design Strategies Based on Clinical Relevance, 13^th European and Global Summit for Nanomedicine organized by CLINAM (Hosted in Switzerland)
Wacker MG (02-2022); Evolution of Dissolution Technologies for Novel Dosage Forms, Dissolution Discussion Group webinar (Hosted in India)
Wacker MG (11-2021); Biopredictions in NanoMedicine: Understanding Clinical Data, Annual Meeting of the German Platform NanoBioMedicine organized by the German Society for Chemical Engineering and Biotechnology (Hosted in Germany)
Wacker MG and Haddouchi S (09-2021); Novel dosage forms (part II): Parenteral products, 3rd SOTAX Congress (Hosted in Switzerland)
Wacker MG (09-2021); Translational Nanomedicine: Biopredictive Tools For Drug Product Development, 2nd International Symposium on Drug Delivery Systems: Innovation, Technology, and Pharmacometrics (Hosted in Brazil)
Wacker MG (07-2021); Nanomedicines Revisited: A Facelift For Personalized Therapy?, 20^thAsian Conference on Clinical Pharmacy (Hosted in Singapore)
Modh H (04-2021); IVIVR for Injectable Nanomedicines – Standing on the Shoulders of Giants, 2^nd ExplainMyResearch Conference (Hosted in Singapore)
Nagpal S (04-2021); High-Throughput Nanoformulation Development – A QbD-Based Approach, 2^nd ExplainMyResearch Conference (Hosted in Singapore)
Wacker MG (11-2020); Nanomedicine at the crossroads: Why good chemistry is not enough, Beilstein Talks (Hosted in Germany)
Wacker MG (10-2020); Nanomedicines today: Quality by Design or Trial and Error?, 12^th European and Global Summit for Nanomedicine organized by CLINAM (Hosted in Switzerland)
Wallenwein CM (06-2020); A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes, SPDS Disso Research Presentations India 2020 Online (Hosted in India)
Wacker MG (05-2020); Nanomedicine 2020 – Tiny Giants Unleashed; 1^st ExplainMyResearch Conference (Hosted in Singapore)
Jung F (05-2020); Nanoparticles and Environmental Protection – A Gordian Knot?; ExplainMyResearch Conference (Hosted in Singapore)
Wacker MG (02-2020); Translational Nanotechnology – Performance Assays for the Next Generation, CRS Local Chapter India, Mumbai (India)
Wacker MG (09-2019); Translational Nanomedicine – How to predict clinical performance?, Global Summit on Regulatory Science, Stresa (Italy)
Wacker MG (06-2018); Nanotechnology in translation – Define, design, produce!, Institute of Materials and Environmental Chemistry/Hungarian Academy of Sciences, Budapest (Hungary)
Wacker MG (03-2018); Challenges in the drug release testing of next-generation nanomedicines, CRS Indian Chapter Meeting, Mumbai (India)
Wacker MG (2016); Designing Nanocarriers For Drug Delivery, NRW-Nanokonferenz, Münster (Germany)
Wacker MG (2016); Challenges in the Drug Release Testing of Next-Generation Nanomedicines, NanoBioMedizin Meeting, Frankfurt (Germany)
Wacker MG (03-2016), Designing Nanomedicines for the Market, 7^th Global Drug Delivery and Formulation Summit, Berlin (Germany)
Wacker MG (08-2015), Nanocarriers for Drug Delivery – Rational Formulation Design, 1^stInternational Symposium on Drug Delivery Systems (SISLIF), Maringá (Brazil)
Wacker MG (03-2015), Die neue Nanomedizin – Von der Idee zum Produkt, NanoBioMedizin Meeting, Frankfurt (Germany)
Wacker MG (02-2015), Nanocarriers for Drug Delivery – Rational Formulation Design, 6^th Global Drug Delivery & Formulation Summit, Düsseldorf (Germany)
Wacker MG, Parnham MJ (05-2014), Achieving a Good Working Relationship with an Academic Research Organization, American Drug Delivery & Formulation Summit, San Diego (USA)
Wacker M (10-2013); Nanocarrier – Entwicklung und Optimierung innovativer Arzneistoffträger, PharmaForum Hessen 2013, Mainz (Germany)
Wacker M (11-2011); Nanopartikel – Eine neue Alternative in der peroralen Arzneistoffformulierung, Pharmaforum 2011 Saarland, St. Ingbert (Germany)

Oral Abstracts, Seminars, and Workshops

Nagpal S, Modh H, Wacker MG (09-2020); Simulating kinetics of liposomal prednisolone phosphate using physiologically based nano-carrier biopharmaceutics model, AAPS-NUS Student Chapter NUS-Monash Conference (Hosted in Singapore).
Wacker MG (06-2020); Nanomedicine in the Spotlight – Unlock your PK, APTI Virtual Seminar (Hosted in India).
Wacker MG (12-2019); Dissolution of drug products containing nanomaterials, USP workshop, Rockville (USA).
Wacker MG (03-2019); Theranostic nanocarriers loaded with nerve growth factor enable enhanced brain recovery after stroke, European Conference on Pharmaceutics, Bologna (Italy).
Wacker MG (02-2018); Advances in Nanosized Drug Delivery – Lost in Translation?, LOSAN Drug Delivery Conference, Frankfurt (Germany).
Wacker MG (10-2017); Safety & Regulatory Aspects of Nanomedicines, National University of Singapore Workshop (Singapore).
Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, PT Indonesia Workshop, Jakarta (Indonesia).
Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Matrix Analytical Technologies Workshop, Kuala Lumpur (Malaysia).
Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, LOSAN Drug Delivery Conference, Frankfurt (Germany).
Wacker MG (2015), Parenteralia, Ophthalmika und perorale Suspensionen – Stabilität, Teilchengrößenwachstum und Freisetzung, FAH Workshop – Pharmaproduktion und Partikel, Bonn (Germany).
Wacker MG (2015), Nanocarriers for Cancer Therapy – Rational Formulation Design, Evonik-LOSAN Workshop, Darmstadt (Germany).
Wacker MG (2014), Rational Formulation Design – Nanomedizin mal anders!, DPhG, Freiburg (Germany).
Janas C, Dressman JB, Wacker MG (2014), The Dispersion Releaser: An Optimal Tool for Selection of Colloidal Dosage Forms, GPEN Meeting, Helsinki (Finland).
Beyer S, Gräfe S, Albrecht V, Wacker MG (2014), Accepting the Challenge of Scale-up – A New Approach for the Targeted Treatment of Colon Cancer based on Nanoparticles overcomes the Limitations of Batch Size, Controlled Release Socienty Annual Meeting, Chicago (USA).
Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation, 38^th Annual Meeting and Exposition of the Controlled Release Society 2011, National Harbor (USA).
Wacker M (2013) Nanocarrier – Trends in Modern Formulation Development, LOSAN Innovative Dosage Forms in Development and Production Workshop, Essen (Germany).

Posters

Gao FG, Villa Nova M, Ashtikar M, Wacker MG (06-2019); Prediction of human pharmacokinetics of subcutaneously administered insulin formulations, PAGE conference, Stockholm (Sweden).
Jung F, Thurn M, Krollik K, Gao FG, Hering I, Eilbrecht E, Weiler M, Günday-Türeli N, Türeli E, Parnham MJ, Wacker MG (06-2019); Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods, PAGE Conference, Stockholm (Sweden).
Gao F, Villa Nova M, Ashtikar M, Wacker MG (06-2018); Prediction of human pharmacokinetics of subcutaneously administered depot formulation using MBPK modeling, PAGE conference, Montreux (Switzerland).
Jung F, Nothnagel L, Gao F, Wacker MG (06-2018); Evaluation of release techniques for nanocarriers on the basis of IVIVC-PBPK modeling, PAGE conference, Montreux (Switzerland).
Nothnagel L, Thurn M, Wacker MG (11-2016); DoE-based development and in vitro drug release testing of TMP-001 loaded nanocarriers, GPEN Meeting, Lawrence (USA).
Jablonka L, Thurn M, Wacker MG (11-2016); In vitro drug release testing of liposomal temoporfin formulations with the dispersion releaser technology, GPEN Meeting, Lawrence (USA).